[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,100
  • Shares Outstanding, K 107,208
  • Annual Sales, $ 11,160 K
  • Annual Income, $ -148,130 K
  • EBIT $ -109 M
  • EBITDA $ -107 M
  • 60-Month Beta 2.38
  • Price/Sales 15.56
  • Price/Cash Flow N/A
  • Price/Book 1.64

Options Overview Details

View History
  • Implied Volatility 194.37% (-6.81%)
  • Historical Volatility 51.83%
  • IV Percentile 61%
  • IV Rank 28.87%
  • IV High 457.33% on 02/12/26
  • IV Low 87.65% on 07/21/26
  • Expected Move (DTE 17) 0.0000 (0.00%)
  • Put/Call Vol Ratio 1.17
  • Today's Volume 13
  • Volume Avg (30-Day) 111
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 10,068
  • Open Int (30-Day) 9,539
  • Expected Range 1.5500 to 1.5500

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 3
  • High Estimate $-0.26
  • Low Estimate $-0.32
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +3.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4250 +8.77%
on 08/03/26
1.7600 -11.93%
on 08/25/26
+0.0900 (+6.16%)
since 07/31/26
3-Month
1.4250 +8.77%
on 08/03/26
2.4500 -36.73%
on 06/02/26
-0.8800 (-36.21%)
since 06/01/26
52-Week
1.3800 +12.32%
on 02/02/26
3.5400 -56.21%
on 11/03/25
-0.3200 (-17.11%)
since 08/29/25

Most Recent Stories

More News
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50%...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- --...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s...

CRBU : 1.5500 (+0.65%)
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing...

CRBU : 1.5500 (+0.65%)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 1.6575
2nd Resistance Point 1.6237
1st Resistance Point 1.5869
Last Price 1.5500
1st Support Level 1.5163
2nd Support Level 1.4825
3rd Support Level 1.4457

See More

52-Week High 3.5400
Fibonacci 61.8% 2.7149
Fibonacci 50% 2.4600
Fibonacci 38.2% 2.2051
Last Price 1.5500
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.